No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Sichuan Huiyu Pharmaceutical Subsidiary Gets Registration for Thiotepa Injection
Huiyu Pharmaceutical (688553.SH): Injectable Setipiprant has obtained the Pharmaceutical registration certificate.
On March 11, Gelonghui reported that Huyue Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary, SiChuan Huyue Haiyue Pharmaceutical Technology Co., Ltd., recently received the "Pharmaceutical Registration Certificate" for its product, injection of Setipiprant, issued by the National Medical Products Administration. Setipiprant is a multifunctional cytotoxic drug, whose chemical structure and pharmacological effects are related to nitrogen mustard. The radiomimetic effects of Setipiprant are believed to be caused by the release of ethylene imine, which damages DNA bonds like radiation. One of the main DNA bond damages occurs through the N-7 guanine alkylation, which disrupts the bond between purine bases and sugar.
Can Mixed Fundamentals Have A Negative Impact on Sichuan Huiyu Pharmaceutical Co., Ltd. (SHSE:688553) Current Share Price Momentum?
Huiyu Pharmaceutical: 2024 Annual Results Express Announcement
2024 Annual Results Express Announcement
Sichuan Huiyu Pharmaceutical Co., Ltd.'s (SHSE:688553) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
